These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 28064387)
21. Correlation between IDH, ATRX, and TERT promoter mutations in glioma. Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259 [TBL] [Abstract][Full Text] [Related]
22. H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696 [TBL] [Abstract][Full Text] [Related]
23. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Jiao Y; Killela PJ; Reitman ZJ; Rasheed AB; Heaphy CM; de Wilde RF; Rodriguez FJ; Rosemberg S; Oba-Shinjo SM; Nagahashi Marie SK; Bettegowda C; Agrawal N; Lipp E; Pirozzi C; Lopez G; He Y; Friedman H; Friedman AH; Riggins GJ; Holdhoff M; Burger P; McLendon R; Bigner DD; Vogelstein B; Meeker AK; Kinzler KW; Papadopoulos N; Diaz LA; Yan H Oncotarget; 2012 Jul; 3(7):709-22. PubMed ID: 22869205 [TBL] [Abstract][Full Text] [Related]
24. High frequency of H3 K27M mutations in adult midline gliomas. Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375 [TBL] [Abstract][Full Text] [Related]
25. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma. Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335 [TBL] [Abstract][Full Text] [Related]
26. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants. Stundon JL; Ijaz H; Gaonkar KS; Kaufman RS; Jin R; Karras A; Vaksman Z; Kim J; Corbett RJ; Lueder MR; Miller DP; Guo Y; Santi M; Li M; Lopez G; Storm PB; Resnick AC; Waanders AJ; MacFarland SP; Stewart DR; Diskin SJ; Rokita JL; Cole KA Neuro Oncol; 2023 Jul; 25(7):1331-1342. PubMed ID: 36541551 [TBL] [Abstract][Full Text] [Related]
28. Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticator. Ryba A; Özdemir Z; Nissimov N; Hönikl L; Neidert N; Jakobs M; Kalasauskas D; Krigers A; Thomé C; Freyschlag CF; Ringel F; Unterberg A; Dao Trong P; Beck J; Heiland DH; Meyer B; Vajkoczy P; Onken J; Stummer W; Suero Molina E; Gempt J; Westphal M; Schüller U; Mohme M Neuro Oncol; 2024 Aug; 26(8):1479-1493. PubMed ID: 38507506 [TBL] [Abstract][Full Text] [Related]
29. Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas. Pinto L; Baidarjad H; Entz-Werlé N; Van Dyck E Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830833 [TBL] [Abstract][Full Text] [Related]
30. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171 [TBL] [Abstract][Full Text] [Related]
31. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101 [TBL] [Abstract][Full Text] [Related]